Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma

Journal of Investigative Dermatology

Volumn 126, Issue 12, 2006, Pages 2658-2663

  Boasberg, Peter D ^a   Hoon, Dave S B ^b   Piro, Lawrence D ^a   Martin, Maureen A ^a   Fujimoto, Akhide ^b   Kristedja, Timothy S ^a   Bhachu, Sandeep ^a   Ye, Xing ^b   Deck, Regina R ^a   O'Day, Steven J ^a  

^a Angeles Clinic and Research Institute   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TYROSINE RELATED PROTEIN 2; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VITILIGO;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; VITILIGO;

EID: 33751073155     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700545     Document Type: Article

References (24)

1. Buendia-Eisman A, Serrano-Ortega S, Ortega del Olmo R (1997) Vitiligo-like lesions in patients with melanoma treated with immunotherapy. Eur J Dermatol 7:522-4
2. Bystryn JC, Rigel D, Friedman RJ, Kopf A (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123:1053-5
3. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC (2001) A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 22:130-6
4. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-4
5. Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ et al. (2000) DSB induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients. Cancer Gene Ther 7:1220-30
6. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsis D et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-18
7. Huang SKS, Okamoto T, Morton DL, Hoon DSB (1998) Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 111:662-7
8. Kemp EH, Waterman EA, Weetman AP (2001) Autoimmune aspects of vitiligo. Autoimmunity 34:65-77
9. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M et al. (2001) Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Investig Dermatol Symp Proc 117:1464-70
10. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK (2004) Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 9:68-72
11. Norlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689-96
12. O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M et al. (2002) Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775-81
13. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M et al. (1999) Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2 granulocyte colony-stimulating factor, and Tamoxifen for patients with metastatic melanoma. J Clin Oncol 17:2752-61
14. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-8
15. Okamoto T, Huang S, Irie RF, Chiang V, Nizze AJ, Morton DL et al. (1998) Anti-tyrosinase-related protein-2 (TRP-2) immune responses in vitiligo patients and melanoma patients responding to active specific immunotherapy. J Invest Dermatol 111:1034-9
16. Ongenae K, Van Geen N, Naeyaert JM (2003) Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16:90-100
17. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-82
18. Phan GQ, Yang JC, Sherry RM, Hwu P, Top SL, Schwartzentruber DJ et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-7
19. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-43
20. Rodriguez-Cuevas S, Lopez-Chavira A, Zepeda del Rio G, Cuadra-Garcia I, Fernandez-Diez J (1998) Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. Arch Med Res 29:155-8
21. Rosenberg SA, White DE (1996) Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-4
22. Schallreuter KU, Levenig C, Berger J (1991) Vitiligo and cutaneous melanoma. Dermatologica 183:239-45
23. Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang S et al. (2002) Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 5:291-9
24. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R et al. (2004) Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22:2671-80